These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25547438)

  • 21. Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
    Yoshimura Y; Takeda T; Kishi Y; Harada T; Nomura A; Washida K; Yoshimura B; Sato K; Yada Y; Aoki S
    J Clin Psychopharmacol; 2017 Jun; 37(3):296-301. PubMed ID: 28306616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.
    Ascher-Svanum H; Novick D; Haro JM; Bertsch J; McDonnell D; Detke H
    BMC Psychiatry; 2013 Sep; 13():224. PubMed ID: 24041270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.
    Frampton JE
    Drugs; 2010 Dec; 70(17):2289-313. PubMed ID: 21080745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
    Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
    J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.
    Hill AL; Sun B; Karagianis JL; Watson SB; McDonnell DP
    BMC Psychiatry; 2011 Feb; 11():28. PubMed ID: 21324135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.
    Case MG; Karagianis JL; Schuh KJ; Hoffmann VP
    Curr Med Res Opin; 2013 Nov; 29(11):1533-7. PubMed ID: 23998459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine: a review of rapid and long-acting parenteral formulations.
    Owen RT
    Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
    Samalin L; Garay R; Ameg A; Llorca PM
    Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
    Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
    BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
    McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
    BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
    Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
    BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia.
    Fefeu M; De Maricourt P; Cachia A; Hoertel N; Vacheron MN; Wehbe E; Rieu C; Olie JP; Krebs MO; Gaillard R; Plaze M
    Psychiatry Res; 2018 Dec; 270():205-210. PubMed ID: 30267984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
    Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
    Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability.
    Mauri MC; Paletta S; Di Pace C; Reggiori A; Rovera C; Fiorentini A; Altamura CA
    Pharmacopsychiatry; 2017 Jul; 50(4):145-151. PubMed ID: 28278537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
    Wu XL; Wang JH; Hu SH; Tao J
    East Asian Arch Psychiatry; 2012 Mar; 22(1):7-11. PubMed ID: 22447799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.